{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:28:01Z","timestamp":1790033281652,"version":"4.0.1"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Stroke"],"published-print":{"date-parts":[[2003,9]]},"abstract":"<jats:p>\n            <jats:bold>\n              <jats:italic>Background and Purpose\u2014<\/jats:italic>\n            <\/jats:bold>\n            NXY-059 has substantial protective effects when administered immediately after the onset of ischemia in a primate model of stroke. This study examined the efficacy of this drug when administered 4 hours after onset, a more clinically relevant time point.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Methods\u2014<\/jats:italic>\n            <\/jats:bold>\n            Before surgery, marmosets were trained and tested on a number of neurological tests, which assessed general neurological function, motor ability, and spatial awareness. Four hours after permanent middle cerebral artery occlusion (pMCAO), marmosets received a bolus of saline (n=13) or NXY-059 (n=13), and osmotic minipumps were implanted, providing 48-hour saline or drug (85 \u03bcmol\/kg per hour) infusion. The monkeys were retested 3 and 10 weeks after surgery. Finally, infarct size was evaluated with histological analysis.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Results\u2014<\/jats:italic>\n            <\/jats:bold>\n            The unbound plasma NXY-059 concentration was 200\u00b19 \u03bcmol\/L after 24-hour infusion, a concentration well tolerated in stroke patients. Drug treatment ameliorated the long-term motor impairment produced by pMCAO; the marmosets were better at using their contralesional, stroke-affected arm than controls at both 3 and 10 weeks. Saline-treated animals had a debilitating spatial neglect at 3 weeks with residual signs evident at 10 weeks. NXY-059 treatment substantially attenuated neglect at 3 weeks, with no deficit being seen at 10 weeks. NXY-059 reduced the overall infarct size by 28% (saline, 324\u00b146 mm\n            <jats:sup>3<\/jats:sup>\n            ; NXY-059, 234\u00b130 mm\n            <jats:sup>3<\/jats:sup>\n            ) with protection to the cortex, white matter, and subcortical structures.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Conclusions\u2014<\/jats:italic>\n            <\/jats:bold>\n            NXY-059 is an effective neuroprotective agent when administered 4 hours after pMCAO in a primate species, attenuating both motor and spatial neglect. The compound also substantially lessened the volume of cerebral damage.\n          <\/jats:p>","DOI":"10.1161\/01.str.0000087790.79851.a8","type":"journal-article","created":{"date-parts":[[2003,8,19]],"date-time":"2003-08-19T00:46:02Z","timestamp":1061253962000},"page":"2228-2233","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":117,"title":["Functional and Histological Evidence for the Protective Effect of NXY-059 in a Primate Model of Stroke When Given 4 Hours After Occlusion"],"prefix":"10.1161","volume":"34","author":[{"given":"Jonathan W.B.","family":"Marshall","sequence":"first","affiliation":[{"name":"From the Medical Research Council Comparative Cognition Team, Department of Experimental Psychology, University of Cambridge, Cambridge, UK (J.W.B.M., R.M.C., L.J.B., R.M.R.), and AstraZeneca R&amp;D Charnwood, Loughborough, UK (A.R.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalyn M.","family":"Cummings","sequence":"additional","affiliation":[{"name":"From the Medical Research Council Comparative Cognition Team, Department of Experimental Psychology, University of Cambridge, Cambridge, UK (J.W.B.M., R.M.C., L.J.B., R.M.R.), and AstraZeneca R&amp;D Charnwood, Loughborough, UK (A.R.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Bowes","sequence":"additional","affiliation":[{"name":"From the Medical Research Council Comparative Cognition Team, Department of Experimental Psychology, University of Cambridge, Cambridge, UK (J.W.B.M., R.M.C., L.J.B., R.M.R.), and AstraZeneca R&amp;D Charnwood, Loughborough, UK (A.R.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind M.","family":"Ridley","sequence":"additional","affiliation":[{"name":"From the Medical Research Council Comparative Cognition Team, Department of Experimental Psychology, University of Cambridge, Cambridge, UK (J.W.B.M., R.M.C., L.J.B., R.M.R.), and AstraZeneca R&amp;D Charnwood, Loughborough, UK (A.R.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Richard","family":"Green","sequence":"additional","affiliation":[{"name":"From the Medical Research Council Comparative Cognition Team, Department of Experimental Psychology, University of Cambridge, Cambridge, UK (J.W.B.M., R.M.C., L.J.B., R.M.R.), and AstraZeneca R&amp;D Charnwood, Loughborough, UK (A.R.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","first-page":"2752\u20132758.","volume":"30","year":"1999","unstructured":"STAIR. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999; 30: 2752\u20132758.","journal-title":"Stroke"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.32.1.190"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(03)02511-3"},{"key":"e_1_3_2_4_2","first-page":"77.","volume":"11","year":"2001","unstructured":"Lees KR, Green AR, Odergren T. Comparison of neuroprotective data for NXY-059 in animal models with the STAIR criteria. Cerebrovasc Dis. 2001; 11 (suppl 4): 77.Abstract.","journal-title":"Cerebrovasc Dis"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704449"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.0000053032.14223.81"},{"key":"e_1_3_2_7_2","unstructured":"Robertson IH Halligan PW Marshall JC. Prospects for the rehabilitation of unilateral neglect. In: Robertson IH Marshall JC eds. Unilateral Neglect: Clinical and Experimental Studies. Hove UK: Lawrence Erlbaum Associates Ltd; 1993: 279\u2013292."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1681.2002.03767.x"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004647-199907000-00008"},{"key":"e_1_3_2_10_2","first-page":"301","volume":"71","year":"1996","unstructured":"Betz AL. Alterations in cerebral endothelial cell function in ischaemia. Adv Neurol. 1996; 71: 301\u2013313.","journal-title":"Adv Neurol"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(01)02618-X"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(02)03469-8"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/10715760100300351"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(02)02922-0"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(00)00170-2"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.0000015346.00054.8b"}],"container-title":["Stroke"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.STR.0000087790.79851.A8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T21:29:45Z","timestamp":1715549385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.STR.0000087790.79851.A8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2003,9]]}},"alternative-id":["10.1161\/01.STR.0000087790.79851.A8"],"URL":"https:\/\/doi.org\/10.1161\/01.str.0000087790.79851.a8","relation":{},"ISSN":["0039-2499","1524-4628"],"issn-type":[{"value":"0039-2499","type":"print"},{"value":"1524-4628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,9]]},"assertion":[{"value":"2002-12-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-05-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-08-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}